| Literature DB >> 32512818 |
Xinpei Ci1,2, Jun Hao1,2, Xin Dong2, Hui Xue2, Rebecca Wu2, Stephen Yiu Chuen Choi2, Anne M Haegert1, Colin C Collins1, Xuefeng Liu3,4, Dong Lin1,2, Yuzhuo Wang1,2.
Abstract
Neuroendocrine prostate cancer (NEPC) is a lethal subtype of prostate cancer. It develops mainly via NE transdifferentiation of prostate adenocarcinoma in response to androgen receptor (AR)-inhibition therapy. The study of NEPC development has been hampered by a lack of clinically relevant models. We previously established a unique and first-in-field patient-derived xenograft (PDX) model of adenocarcinoma (LTL331)-to-NEPC (LTL331R) transdifferentiation. In this study, we applied conditional reprogramming (CR) culture to establish a LTL331 PDX-derived cancer cell line named LTL331_CR_Cell. These cells retain the same genomic mutations as the LTL331 parental tumor. They can be continuously propagated in vitro and can be genetically manipulated. Androgen deprivation treatment on LTL331_CR_Cells had no effect on cell proliferation. Transcriptomic analyses comparing the LTL331_CR_Cell to its parental tumor revealed a profound downregulation of the androgen response pathway and an upregulation of stem and basal cell marker genes. The transcriptome of LTL331_CR_Cells partially resembles that of post-castrated LTL331 xenografts in mice. Notably, when grafted under the renal capsules of male NOD/SCID mice, LTL331_CR_Cells spontaneously gave rise to NEPC tumors. This is evidenced by the histological expression of the NE marker CD56 and the loss of adenocarcinoma markers such as PSA. Transcriptomic analyses of the newly developed NEPC tumors further demonstrate marked enrichment of NEPC signature genes and loss of AR signaling genes. This study provides a novel research tool derived from a unique PDX model. It allows for the investigation of mechanisms underlying NEPC development by enabling gene manipulations ex vivo and subsequent functional evaluations in vivo.Entities:
Keywords: conditional reprogramming culture; neuroendocrine prostate cancer; patient-derived xenograft
Mesh:
Substances:
Year: 2020 PMID: 32512818 PMCID: PMC7349646 DOI: 10.3390/cells9061398
Source DB: PubMed Journal: Cells ISSN: 2073-4409 Impact factor: 6.600
Figure 1Establishment, application, and molecular characterization of conditionally reprogrammed cells derived from the LTL331 PDX. (A) Schematic showing the conditional reprogramming (CR) culture establishment process. The LTL331 prostatic adenocarcinoma PDX can transdifferentiate to neuroendocrine prostate cancer (NEPC) (LTL331R) after host mouse castration-induced tumor regression (LTL331_Cas) [10]. Fresh tumor tissue from LTL331 was enzymatically dissociated into single cells. The cells were then cocultured with irradiated 3T3-J2 feeder cells to establish LTL331_CR_Cells. The CR cells were grafted under the renal capsule of host mice to establish CR cells-derived xenografts, namely LTL331_CR_ Tumor. (B) Representative images of LTL331_CR_Cells. Under the light microscope, small colonies of epithelial tumor cells can be observed 3 days after initial plating as highlighted by the white dash (left panel). Faster growing large colonies can be observed after one week as shown in the right panel. Scale bar, 200 μm. (C) Growth curve of LTL331_CR_Cell. The CR cells were serially passaged and the cell numbers were recorded at each passage until the culture was terminated. A growth curve of population doublings versus time (days) is plotted. (D) Representative image of LTL331_CR_Cell following genetic manipulation. Cells were transduced with lentivirus to express the mCherry fluorescent protein. Scale bar, 100 μm. (E) Representative image of LTL331_CR_Tumor growing under the renal capsule of a mouse. The green dash highlights two tumors grafted in one kidney. Scale bar, 2 mm. (F–G) Mutation analysis of expressed transcripts across the LTL331-derived models. Mutation type and frequency was analyzed with RNA-seq data. The percentage of each mutation type is stacked into one bar, with different types indicated by the corresponding colors (F). Representative gene mutations are shown (G).
Figure 2LTL331_CR_Cell is androgen independent with stem-like features. (A). Growth curve of LTL331_CR_Cells under androgen deprivation therapy (ADT) conditions. CR cells were cultured in medium containing charcoal stripped serum (CSS) to mimic ADT. The cells were passaged and cell numbers were recorded at each passage. The blue curve shows cells grown in CSS-containing medium, while the red curve shows cells grown in normal medium containing FBS. The red curve is the same as Figure 1C. (B) Inactivation of AR signaling in LTL331_CR_Cells. Transcriptomic analysis using gene set enrichment analysis (GSEA) shows that androgen response is downregulated in LTL331_CR_Cells compared to the parental LTL331. (C) The transcriptome of LTL331_CR_Cells partially resembles that of LTL331 post-castration. The top 100 upregulated and downregulated genes from 12-week post-castrated LTL331 were utilized as gene sets (i.e., 331 CAS 12W_UP 100, 331 CAS 12W_DOWN 100). GSEA comparing LTL331_CR_Cells to the parental LTL331 shows that a very similar set of castration-response genes are upregulated (left panel) and downregulated (right panel). (D) GSEA shows that select cancer hallmarks are enriched in LTL331_CR_Cells compared to post-castrated LTL331. The y-axis represents normalized enrichment scores (NES). The nominal p-values of all gene sets are less than 0.05. (E) Heatmap showing stem cell and cell lineage marker expression in LTL331_CR_Cells. Log-2 expression fold changes of select stem, basal, luminal, and intermediate transient amplifying (TA) cell markers were compared between LTL331_CR_Cell, 12-week post-castrated LTL331, LTL331R, and the parental LTL331.
Figure 3Characterization of LTL331_CR_Tumor as NEPC. (A) Representative images showing IHC staining of LTL331, LTL331R, and LTL331_CR_Tumor. H&E, epithelial tumor marker pan-CK, proliferation marker Ki67, NE marker CD56, AR, and AR signaling marker PSA were stained as indicated in the images. Scale bar, 100 μm. (B) AR and NE scores of LTL331_CR_Tumor. NE and AR scores were calculated using transcriptomic data from LTL331_CR_Tumor. The scores were also calculated for other independent PDX models and LTL331_CR_Cell. Sample types are differentially colored based on their histopathological classifications.